CEGE

CEGE Articles

Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.   We published a full...
  Smart Investors Are Quietly Loading Up on These “Dividend Legends” If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like...
Freddie Mac (FRE) is one sale at $.65. A day-trader’s dream, down from a 52-week high of $65.88. Fannie Mae (FNM) Almost a better deal. Sells off to $.65 from 52-week high of $68.60. Biodel (BIOD)...
Ford (F) Oil moves up. Drops to $4.25 from a 52-week high of $9.24. Nexmed (NEXM) Drug trial problems. Falls to $.23 from a 52-week high of $.1.87. Cell Genesys (CEGE) Drug trial problems. Plunges to...
Cell Genesys CEO Stephen A. Sherwin, M.D made $1.3 million last year, with $577,500 coming from base salary. He did so well, in the eyes of the board, that his base was raised to $602,500. Who knows...
AMAG Pharmaceuticals (NASDAQ: AMAG) has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI) beginning May 19, 2008. AMAG shares up $1.26 at $39.85. The 52-week range is $38.16 to $72.95. Cell...
Cell Genesys, Inc. (NASDAQ: CEGE) plans to offer 7.1 million shares of common stock and warrants at an equivalent of $4.22 per share with a single institutional investor, for an equity offering...
Cell Genesys, Inc. (NASDAQ: CEGE) has announced a global alliance with Takeda Pharmaceutical Company Limited in Japan.  The companies will develop and commercialize Cell Genesys’ GVAX...
Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week...
Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head.  But Biotechs are also a source of safety IF they are winners, and...
Stock Tickers: DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVO Many of the recent biotech implosions are always interesting to see if short sellers are getting out of the way or adding pressure.  Out...
Vertex (VRTX-NASDAQ) is seeing quite a bit of trading today ahead of a data presentation tomorrow.  This one may have been very active all on its own, but since Dendreon (DNDN-NASDAQ) made its...
Cell Genesys, Inc. (CEGE-NASDAQ) has done what many small biotechs do that are in need of cash: sell shares in a private placement "PIPE" after a sharp stock run-up.  It has entered into definitive...